20
Participants
Start Date
February 24, 2021
Primary Completion Date
July 22, 2024
Study Completion Date
July 22, 2024
CMP-001
Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
Nivolumab
Nivolumab 360 mg IV is administered Q3W.
University of Pittsburgh Medical Center / Hillman Cancer Center, Pittsburgh
Thomas Jefferson University, Philadelphia
West Virginia University, Morgantown
Duke University Cancer Institute, Durham
University Cancer & Blood Center, Athens
Cleveland Clinic, Weston
University of Louisville Health Care, Louisville
The Ohio State University Wexner Medical Center, Columbus
University of Iowa Hospitals & Clinics, Iowa City
University of Arkansas for Medical Sciences, Little Rock
Texas Oncology, Sammons Cancer Center, Dallas
Mayo Clinic Arizona, Phoenix
USC/Norris Comprehensive Cancer Center, Los Angeles
University of California, Los Angeles, Los Angeles
California Cancer Associates for Research & Excellence, Inc., San Marcos
Moores Cancer Center at UC San Diego Health, La Jolla
USC Norris Oncology/Hematology-Newport Beach, Newport Beach
Seattle Cancer Care Alliance, Seattle
Hartford Healthcare, Hartford
Atlantic Health, Morristown
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Regeneron Pharmaceuticals
INDUSTRY